Seeking Alpha

Biogen Idec Inc. (BIIB)

()

News & PR
Market Currents

Buzz
Twitter: BIIB

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

Facet Rebuffs Biogen: Will a White Knight Emerge?

Dec 21 • EP Vantage • 1 Comment
Facet Board Pleased with Rejection of Biogen Bid

Dec 20 • The Burrill Report • Comment!
Baupost to Purchase More Facet Biotech: What About Biogen Idec?

Dec 16 • Market Folly • 2 Comments
InfoTech Sector on the Rise

Dec 16 • Scott Martindale • Comment!
30 'Magic Formula' Companies

Dec 16 • Value Expectations • 1 Comment
S&P 500's Ten Cheapest Stocks

Dec 8 • Value Expectations • 5 Comments
Wall Street Breakfast: Must-Know News

Dec 4 • Suzanne Miller • 11 Comments
December's Game Plan for Biotech

Dec 1 • Justin M. Hall • 4 Comments
Financing Drug Discovery: Recent Deals

Nov 26 • The Burrill Report • 1 Comment
Spectrum Pharma: Zevalin Sales Ramp Up

Nov 22 • Justin M. Hall • 23 Comments
U.S. Healthcare Legislation Investment Impact

Nov 9 • Richard Shaw • 20 Comments
Spectrum Pharma: CMS Rules in Favor of Zevalin

Nov 3 • Justin M. Hall • 6 Comments
Healthcare Profits: Assessing Company Sensitivity to Obamacare

Oct 30 • Richard Shaw • 11 Comments
Spectrum Pharma: Zevalin Has Blockbuster Potential

Oct 25 • Justin M. Hall • 36 Comments
Friday Options Recap

Oct 23 • Frederic Ruffy • 4 Comments
Report from Europe: Traders are Buying the Earnings Story

Oct 23 • The Mole • 2 Comments
Wall Street Breakfast: Must-Know News

Oct 20 • Suzanne Miller • 14 Comments
Galleon Group's 50 Largest Holdings

Oct 18 • AlphaClone • 10 Comments
Stage Set for Acorda Bounce?

Oct 11 • M. E. Garza • 1 Comment
11 Ache-Free Investment Opportunities in Neuropathic Pain

Sep 30 • Michael Becker • 1 Comment
Access Pharma: MuGard, Pipeline Make for Appealing Acquisition Possibilities

Sep 30 • Mike Havrilla • 4 Comments
Financing Activity for Biotech Deals Heats Up

Sep 27 • The Burrill Report • 2 Comments
How Zevalin Is Helping Spectrum

Sep 24 • Justin M. Hall • 15 Comments
Biogen Launches Hostile Bid to Acquire Facet Biotech

Sep 23 • Zacks.com • Comment!
Elan Pays Price for Secret J&J Deal

Sep 15 • EP Vantage • 3 Comments
Equities Shrug Off Protectionist Fears

Sep 15 • The Mole • 4 Comments
Wall Street Breakfast: Must-Know News

Sep 15 • SA Editors • 11 Comments
Report from Europe: Trade Wars are Never Good News for Stocks

Sep 14 • The Mole • 3 Comments
Wall Street Breakfast: Must-Know News

Sep 14 • SA Editor Rachael Granby • 31 Comments
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up

Sep 11 • Justin M. Hall • 23 Comments
Facet Biotech Should Dig in Its Heels over Biogen Bid

Sep 8 • EP Vantage • 2 Comments
Novartis: Powering into the Multiple Sclerosis Market

Sep 8 • Richard Sater • 3 Comments
Exiting Facet Biotech on Biogen's Offer

Sep 7 • ValueHuntr • 2 Comments
Summer Ends with Biotech Buying Spree

Sep 6 • The Burrill Report • Comment!
Wall Street Breakfast: Must-Know News

Sep 4 • SA Editor Rachael Granby • 11 Comments
Bayer's Bold New Bet Fails to Rain on Spectrum Pharma

Sep 4 • Michael Becker • 10 Comments
Three Recent Biotech Activist Wins by Carl Icahn

Aug 31 • Michael Becker • 4 Comments
Spectrum Pharmaceuticals: The Labor Day Catalyst

Aug 20 • Justin M. Hall • 18 Comments
Spotlight on Biotech: 10 Promising Companies

Aug 9 • Ron Sommer • 2 Comments
Elan / Johnson & Johnson Deal Going Through More Twists and Turns

Aug 8 • EP Vantage • 1 Comment
FDA Calendar Updates: Orexo, Novo Nordisk, King, Isis, Facet

Aug 7 • Mike Havrilla • 1 Comment

Biogen Idec Inc. (BIIB)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers